Study of BGB-26808 with or without Tislelizumab for Advanced Solid Tumors
This study is testing a new drug called BGB-26808, either by itself or combined with another drug called Tislelizumab, for people with advanced solid tumors. BGB-26808 is given as a daily pill, and Tislelizumab is given through an IV. The main goal is to find the safest and most effective dose of BGB-26808. We're looking for participants aged 18 and older who have advanced solid tumors and a good general health status (ECOG Performance Status ≤ 1). Success for this part of the study means understanding the side effects and finding the best dose of BGB-26808. The current recruitment status is unclear.
- Study design
- This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It is a multicenter study, not randomized, and plans to enroll 217 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for side effects from the first dose up to 90 days after the last dose, or until a new cancer treatment starts, for up to approximately 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
At a glance
Conditions
NCT05981703
Where you'd take part
This study runs at 28 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Auckland City Hospital
Auckland, New Zealandno site contact published
Recruiting
City of Hope National Medical Center
Duarte, Californiano site contact published
Recruiting
Hangzhou First Peoples Hospital
Hangzhou, Zhejiang, Chinano site contact published
Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, Chinano site contact published
Recruiting
Harbour Cancer and Wellness
Auckland, New Zealandno site contact published
Recruiting
Health New Zealand Te Whatu Ora Lakes Rotorua Hospital
Rotorua, New Zealandno site contact published
Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, Chinano site contact published
Recruiting
Icahn School of Medicine At Mount Sinai
New York, New Yorkno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Study Director · STUDY_DIRECTOR · BeOne Medicines
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)From the first dose of study drug(s) to 90 days after the last dose or initiation of a new anticancer therapy, whichever occurs first; up to approximately 12 months
Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.
- Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-26808Approximately 1 month
MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached.
- Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-26808Approximately 1 month
RDFE of BGB-26808 alone or in combination with tislelizumab will be determined based upon the MTD or MAD.
- Phase 1b: Overall Response Rate (ORR)Approximately 6 months
ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.